Search
Ketanserin
go.drugbank.com/drugs/DB12465InvestigationalKetanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDoxacurium
go.drugbank.com/drugs/DB01135ApprovedWithdrawnDoxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Cathine
go.drugbank.com/drugs/DB01486ExperimentalIllicitIt belongs to the phenethylamine and amphetamine chemical classes. In the United States, it is classified as a Schedule IV controlled substance.
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor. … Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple … CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Sulfachlorpyridazine
go.drugbank.com/drugs/DB11461ExperimentalVet approvedA sulfonamide antimicrobial used for urinary tract infections and in veterinary medicine.
Mixtures: TP-KSM 125/625 mg/g Water Soluble PowderKW-7158
go.drugbank.com/drugs/DB05498ExperimentalThe therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion … (involuntary abnormal contraction of the bladder).
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.
Mebutamate
go.drugbank.com/drugs/DB06797ApprovedMebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a
Oxitriptan
go.drugbank.com/drugs/DB02959ApprovedInvestigationalNutraceuticalWithdrawnMore study is needed to determine efficacy in treating depression. … 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in